Tissue Regeneration Therapeutics Announces the Launch of their NEW Cosmetic Brand TRT CELLULAR
Toronto, ON (June 17, 2021) – J. E. Davies, President and CEO of Tissue Regeneration Therapeutics (TRT), announced today the launch of a new exclusive ecommerce website for TRT’s newly branded cosmetic products TRT CELLULAR. One of TRT’s distinctive platform technologies, TRT …
Tissue Regeneration Therapeutics and RoosterBio Inc. Form Strategic Alliance to Commercialize Umbilical Cord Tissue Cell Technology
Toronto, ON, Canada, December 10, 2018 — Today Tissue Regeneration Therapeutics Inc. (TRT) and RoosterBio Inc. (RBI) announce an important strategic alliance to advance their shared goal of accelerating the development of the Regenerative Medicine and Cellular Therapy fields. This collaboration will …
Tissue Regeneration Therapeutics Receives Latest Notice of Patent Grant from the United States Patent Office
Toronto, Canada, April 6th 2017: Tissue Regeneration Therapeutics Inc. (TRT) today announced it has received notice from the United States Patent and Trademark Office that its patent: Progenitor Cells from Wharton’s Jelly of Human Umbilical Cord, was grated on April 4th, 2017 …
Tissue Regeneration Therapeutics engineered mesenchymal stromal cells advance monoclonal antibody therapy
Toronto, Canada, August 15th 2016: Tissue Regeneration Therapeutics Inc. (TRT) today announced that a team of Canadian researchers have for the first time shown that TRT’s engineered mesenchymal stromal cell product (eTXP) can be used to deliver therapeutically useful monoclonal antibodies (mAbs) …
Tissue Regeneration Therapeutics Grants Excusive License for Perivascular Umbilical Cord Stromal/Stem Cell Technology for Family Banking
Toronto, Canada, February 16th 2016: Tissue Regeneration Therapeutics (TRT) announced today an exclusive licensing agreement in the United Kingdom, most of Continental Europe, Ireland, Iceland, UAE, Kuwait, Qatar, Oman, Bahrain, Jordan, and Lebanon. The licensee will now be able to offer families …
Tissue Regeneration Therapeutics Inc. receives notice of latest patent grant from the State of Israel Patent Office
Toronto, Canada, January 3rd 2016: Tissue Regeneration Therapeutics Inc. (TRT) today announced it has received notice from the State of Israel Patent office that its patent: IMMUNE PRIVILEDGED AND MODULATORY PROGENITOR CELLS, has been granted as Israel patent 195067. This latest addition …
Tissue Regeneration Therapeutics Inc. Grants Excusive Canadian License for Its Patent: Viable Cells From Frozen Umbilical Cord Tissue, For Family Banking
Toronto, Canada, September 25th 2015: Tissue Regeneration Therapeutics (TRT) announced today an exclusive licensing agreement with Cells for Life, which will now be able to offer families in Canada the ability to extract stem cells from cryogenically stored tissue surrounding the vessels …
Tissue Regeneration Therapeutics Inc. receives notice of latest patent grant from the United States Patent Office
Toronto, Canada, March 30th 2015: Tissue Regeneration Therapeutics Inc. (TRT) today announced it has received notice from the United States Patent and Trademark Office that its patent: GENETICALLY MODIFIED HUMAN UMBILICAL CORD PERIVASCULAR CELLS FOR PROPHYLAXIS AGAINST OR TREATMENT OF BIOLOGICAL OR …
Tissue Regeneration Therapeutics Inc. receives notice of latest patent grant from the Korean Intellectual Property Office
Toronto, Canada, March 24th 2015: Tissue Regeneration Therapeutics Inc. (TRT) today announced it has received notice from the Korean Intellectual Property Office that its patent: IMMUNE PRIVILEDGED AND MODULATORY PROGENITOR CELLS, has been granted as Korean Patent 10-1507174. This latest addition to …
Tissue Regeneration Therapeutics Inc. reaches final milestone of a $3.25 Million funding for development of its Mesenchymal Cell therapeutics platform
Toronto, Canada, October 17th 2014: Tissue Regeneration Therapeutics Inc. (TRT) today announced it has completed the final milestone in a structured royalty sale transaction with SWK Holdings Corporation. The transaction, valued at US$3.25 million, was based on the strength of two TRT …
- 1
- 2
Lastest Posts
